FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003391833> ?p ?o ?g. }

• W2003391833 endingPage "243" @default.
• W2003391833 startingPage "243" @default.
• W2003391833 abstract "Background: Lipid-lowering therapy is costly but effective at reducing coronary heart disease (CHD) risk. Objective: To assess the cost-effectiveness and public health impact of Adult Treatment Panel III (ATP III) guidelines and compare with a range of risk- and age-based alternative strategies. Design: The CHD Policy Model, a Markov-type cost-effectiveness model. Data Sources: National surveys (1999 to 2004), vital statistics (2000), the Framingham Heart Study (1948 to 2000), other published data, and a direct survey of statin costs (2008). Target Population: U.S. population age 35 to 85 years. Time Horizon: 2010 to 2040. Perspective: Health care system. Intervention: Lowering of low-density lipoprotein cholesterol with HMG-CoA reductase inhibitors (statins). Outcome Measure: Incremental cost-effectiveness. Results of Base-Case Analysis: Full adherence to ATP III primary prevention guidelines would require starting (9.7 million) or intensifying (1.4 million) statin therapy for 11.1 million adults and would prevent 20 000 myocardial infarctions and 10 000 CHD deaths per year at an annual net cost of $3.6 billion ($42 000/QALY) if low-intensity statins cost $2.11 per pill. The ATP III guidelines would be preferred over alternative strategies if society is willing to pay $50 000/QALY and statins cost $1.54 to $2.21 per pill. At higher statin costs, ATP III is not cost-effective; at lower costs, more liberal statin-prescribing strategies would be preferred; and at costs less than $0.10 per pill, treating all persons with low-density lipoprotein cholesterol levels greater than 3.4 mmol/L (>130 mg/dL) would yield net cost savings. Results of Sensitivity Analysis: Results are sensitive to the assumptions that LDL cholesterol becomes less important as a risk factor with increasing age and that little disutility results from taking a pill every day. Limitation: Randomized trial evidence for statin effectiveness is not available for all subgroups. Conclusion: The ATP III guidelines are relatively cost-effective and would have a large public health impact if implemented fully in the United States. Alternate strategies may be preferred, however, depending on the cost of statins and how much society is willing to pay for better health outcomes. Funding: Flight Attendants' Medical Research Institute and the Swanson Family Fund. The Framingham Heart Study and Framingham Offspring Study are conducted and supported by the National Heart, Lung, and Blood Institute." @default.
• W2003391833 created "2016-06-24" @default.
• W2003391833 creator A5007133304 @default.
• W2003391833 creator A5011978959 @default.
• W2003391833 creator A5020104782 @default.
• W2003391833 creator A5026789706 @default.
• W2003391833 creator A5028632973 @default.
• W2003391833 creator A5043982361 @default.
• W2003391833 creator A5076818985 @default.
• W2003391833 creator A5077513309 @default.
• W2003391833 creator A5086681800 @default.
• W2003391833 date "2009-02-17" @default.
• W2003391833 modified "2023-10-02" @default.
• W2003391833 title "Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering" @default.
• W2003391833 cites W1584135845 @default.
• W2003391833 cites W180141685 @default.
• W2003391833 cites W1963532988 @default.
• W2003391833 cites W1969054950 @default.
• W2003391833 cites W1973871097 @default.
• W2003391833 cites W1977756333 @default.
• W2003391833 cites W1979710673 @default.
• W2003391833 cites W1981977618 @default.
• W2003391833 cites W1985967126 @default.
• W2003391833 cites W1993480627 @default.
• W2003391833 cites W1997686650 @default.
• W2003391833 cites W1998609175 @default.
• W2003391833 cites W2000182266 @default.
• W2003391833 cites W2008227566 @default.
• W2003391833 cites W2010518325 @default.
• W2003391833 cites W2012880565 @default.
• W2003391833 cites W2017289592 @default.
• W2003391833 cites W2024503111 @default.
• W2003391833 cites W2027399810 @default.
• W2003391833 cites W2040982838 @default.
• W2003391833 cites W2043180355 @default.
• W2003391833 cites W2045753757 @default.
• W2003391833 cites W2048488630 @default.
• W2003391833 cites W2048859524 @default.
• W2003391833 cites W2050025296 @default.
• W2003391833 cites W2055974666 @default.
• W2003391833 cites W2060203449 @default.
• W2003391833 cites W2061422396 @default.
• W2003391833 cites W2066157763 @default.
• W2003391833 cites W2066457780 @default.
• W2003391833 cites W2067236087 @default.
• W2003391833 cites W2081083774 @default.
• W2003391833 cites W2083059885 @default.
• W2003391833 cites W2085522500 @default.
• W2003391833 cites W2086437366 @default.
• W2003391833 cites W2087395156 @default.
• W2003391833 cites W2093380756 @default.
• W2003391833 cites W2095152560 @default.
• W2003391833 cites W2098522155 @default.
• W2003391833 cites W2104761168 @default.
• W2003391833 cites W2105630562 @default.
• W2003391833 cites W2106343349 @default.
• W2003391833 cites W2118310760 @default.
• W2003391833 cites W2119768278 @default.
• W2003391833 cites W2125730125 @default.
• W2003391833 cites W2130105937 @default.
• W2003391833 cites W2134312762 @default.
• W2003391833 cites W2135973591 @default.
• W2003391833 cites W2137253991 @default.
• W2003391833 cites W2140232165 @default.
• W2003391833 cites W2145045425 @default.
• W2003391833 cites W2150023997 @default.
• W2003391833 cites W2155598961 @default.
• W2003391833 cites W2159405284 @default.
• W2003391833 cites W2160222342 @default.
• W2003391833 cites W2161116139 @default.
• W2003391833 cites W2170714183 @default.
• W2003391833 cites W2247997571 @default.
• W2003391833 cites W2336413601 @default.
• W2003391833 cites W2341112456 @default.
• W2003391833 cites W2738970206 @default.
• W2003391833 doi "https://doi.org/10.7326/0003-4819-150-4-200902170-00005" @default.
• W2003391833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19221376" @default.
• W2003391833 hasPublicationYear "2009" @default.
• W2003391833 type Work @default.
• W2003391833 sameAs 2003391833 @default.
• W2003391833 citedByCount "169" @default.
• W2003391833 countsByYear W20033918332012 @default.
• W2003391833 countsByYear W20033918332013 @default.
• W2003391833 countsByYear W20033918332014 @default.
• W2003391833 countsByYear W20033918332015 @default.
• W2003391833 countsByYear W20033918332016 @default.
• W2003391833 countsByYear W20033918332017 @default.
• W2003391833 countsByYear W20033918332018 @default.
• W2003391833 countsByYear W20033918332019 @default.
• W2003391833 countsByYear W20033918332020 @default.
• W2003391833 countsByYear W20033918332021 @default.
• W2003391833 countsByYear W20033918332023 @default.
• W2003391833 crossrefType "journal-article" @default.
• W2003391833 hasAuthorship W2003391833A5007133304 @default.
• W2003391833 hasAuthorship W2003391833A5011978959 @default.
• W2003391833 hasAuthorship W2003391833A5020104782 @default.
• W2003391833 hasAuthorship W2003391833A5026789706 @default.
• W2003391833 hasAuthorship W2003391833A5028632973 @default.

• next